| Jun 21 |
Hims & Hers defended at BofA as Lilly fights compounded GLP-1s
|
| Jun 18 |
Hims & Hers: The Undervalued Gem Poised For Growth
|
| Jun 16 |
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
|
| Jun 13 |
Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead
|
| Jun 13 |
Explore These 3 US Growth Companies With High Insider Ownership
|
| Jun 10 |
Capricor Advances in DMD Therapy With Positive Study Data
|
| Jun 10 |
Hims & Hers: Ready For Takeoff
|
| Jun 10 |
Hims & Hers: Beware Of Chasing Weight Loss Drugs FOMO
|
| Jun 10 |
Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
|
| Jun 7 |
Looking Into Hims & Hers Health's Recent Short Interest
|
